Two hour glucose post loading: A biomarker of cardiovascular risk in isolated clinic hypertension

Journal of Hypertension

Volumn 29, Issue 4, 2011, Pages 749-757

  Martin, Catherine A ^a   Cameron, James D ^b   Chen, Suzi S ^a   McGrath, Barry P ^a,c  

^a MONASH UNIVERSITY   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

^c DANDENONG HOSPITAL   (Australia)

Author keywords

autonomic function; circulating biomarkers; glucose; insulin resistance; isolated clinic hypertension; pulse wave velocity; white coat hypertension

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; N(G),N(G) DIMETHYLARGININE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADULT; AGE; AGED; ARTERIAL STIFFNESS; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD PRESSURE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; PRIORITY JOURNAL; PULSE WAVE; RISK ASSESSMENT; WAIST CIRCUMFERENCE; WHITE COAT HYPERTENSION;

EID: 79952747700     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328342eeeb     Document Type: Article

References (44)

1. Sega R, Trocino G, Lanzarotti A, Carugo S, Cesana G, Schiavina R, et al. Alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: data from the general population (Pressione Arteriose Monitorate E Loro Associazioni [PAMELA] Study). Circulation 2001; 104:1385-1392. (Pubitemid 32880151)
2. Niiranen TJ, Jula AM, Kantola IM, Reunanen A. Prevalence and determinants of isolated clinic hypertension in the Finnish population: the Finn-HOME study. J Hypertens 2006; 24:463-470. (Pubitemid 43261910)
3. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Polo Friz H, et al. Long-term risk of sustained hypertension in white-coat or masked hypertension. Hypertension 2009; 54:226-232.
4. Mancia G, Bombelli M, Facchetti R, Madotto F, Quarti-Trevano F, Grassi G, Sega R. Increased long-term risk of new-onset diabetes mellitus in whitecoat and masked hypertension. J Hypertens 2009; 27:1672-1678.
5. Boyko EJ, Barr EL, Zimmet PZ, Shaw JE. Two-hour glucose predicts the development of hypertension over 5 years: the AusDiab study. J Hum Hypertens 2008; 22:168-176. (Pubitemid 351266484)
6. Boyko EJ, Shaw JE, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. A prospective study of glycemia, body size, insulin resistance and the risk of hypertension in Mauritius. J Hypertens 2008; 26:1742-1749.
7. Barr EL, Boyko EJ, Zimmet PZ, Wolfe R, Tonkin AM, Shaw JE. Continuous relationships between nondiabetic hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study. Diabetologia 2009; 52:415-424.
8. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22:233-240. (Pubitemid 29056916)
9. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. STOPNIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486-494. (Pubitemid 37430502)
10. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome: a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diab Med 2006; 23:469-480.
11. WHO. Definition, diagnosis and classification of diabetes mellitus and its complications; part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organisation, Department of Noncommunicable Disease Surveillance; 1999.
12. Ho LT, Chou TY, Chen RL, Deng PR, Lin WH, Jap TS, Tsai ST. The diagnostic criteria of diabetic autonomic neuropathy. Proc Natl Sci Counc ROC 1982; 6:286-291.
13. Wolfe R, Carlin JB. Sample-size calculation for a log-transformed outcome measure. Control Clin Trials 1999; 20:547-554. (Pubitemid 30001694)
14. DECODE Study Group. Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European Cohorts. Diab Care 2003; 26:61-69.
15. Helvaci MR, Kaya H, Duru M, Yalcin A. What is the relationship between white coat hypertension and dyslipidemia? Int Heart J 2008; 49:87-93. (Pubitemid 351663726)
16. Bjorklund K, Lind L, Vessby B, Andren B, Lithell H. Different metabolic predictors of white-coat and sustained hypertension over a 20-year followup period: a population-based study of elderly men. Circulation 2002; 106:63-68. (Pubitemid 34747443)
17. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique, a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237:E214-E223. (Pubitemid 9249478)
18. Meyer C, Pimenta W, Woerle HJ, Van Haeften T, Szoke E, Mitrakou A, Gerich J. Different mechanisms for impaired fasting glucose and impaired postprandial glucose tolerance in humans. Diabetes Care 2006; 29:1909-1914. (Pubitemid 44156651)
19. Natali A, Santoro D, Palombo C, Cerri M, Ghione S, Ferrannini E. Impaired insulin action on skeletal muscle metabolism in essential hypertension. Hypertension 1991; 17:170-178.
20. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and h diagnostic criteria. Arch Intern Med 2001; 161:397-405.
21. Tominaga M, Igarashi K, Eguchi H, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease but not impaired fasting glucose. Diab Care 1999; 22:920-924. (Pubitemid 29241045)
22. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ. Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42:926-931. (Pubitemid 29369599)
23. Meigs JB ND, D'Agostino RB, Wilson PW. Fasting and postchallenge glycaemia and cardiovascular disease risk: The Framingham Offspring Study. Diab Care 2002; 25:1845-1850. (Pubitemid 41071098)
24. Lin HJ, Lee BC, Ho YL, Lin YH, Chen CY, Hsu HC, et al. Postprandial glucose improves the risk prediction of cardiovascular death beyond the metabolic syndrome in the nondiabetic population. Diab Care 2009; 32:1721-1726.
25. Mancia G, Parati G, Borghi C, Ghironzi G, Andriani E, Marinelli L, et al. Hypertension prevalence, awareness, control and association with metabolic abnormalities in the San Marino population: the SMOOTH study. J Hypertens 2006; 24:837-843. (Pubitemid 43670453)
26. Julius S, Mejia A, Jones K, Krause L, Schork N, van de Ven C, et al. 'White coat' versus 'sustained' borderline hypertension in Tecumseh, Michigan. Hypertension 1990; 16:617-623.
27. Helvaci MR, Kaya H, Seyhanli M, Yalcin A. White coat hypertension in definition of metabolic syndrome. Int Heart J 2008; 49:449-457.
28. Helvaci MR, Sevinc A, Camci C, Yalcin A. Treatment of white coat hypertension with metformin. Int Heart J 2008; 49:671-679.
29. Silva JA, Barbosa L, Bertoquini S, Maldonado J, Polonia J. Relationship between aortic stiffness and cardiovascular risk factors in a population of normotensives, white-coat normotensives, white-coat hypertensives, sustained hypertensives and diabetic patients. Rev Port Cardiol 2004; 23:1533-1547. (Pubitemid 40203757)
30. Ribeiro L, Gama G, Santos A, Asmar R, Martins L, Polonia J. Arterial distensibility in subjects with white-coat hypertension with and without diabetes or dyslipidaemia: comparison with normotensives and sustained hypertensives. Blood Press Monit 2000; 5:11-17. (Pubitemid 30197907)
31. McEniery CM, Wilkinson IB, Avolio AP. Age, hypertension and arterial function. Clin Exp Pharmacol Physiol 2007; 34:655-671.
32. Grassi G, Seravelle G, Quarti Trevano F, Dell'Oro R, Bolla G, Cuspidi C, et al. Neurogenic abnormalities in masked hypertension. Hypertension 2007; 50:537-542. (Pubitemid 47312241)
33. Smith PA, Graham LN, Mackintosh AF, Stoker JB, Mary DA. Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 2004; 17:217-222. (Pubitemid 38293325)
34. Madsen LB, Rasmussen JK, Moller DS, Nyvad O, Pedersen EB. Heart rate variability in white-coat hypertension. Blood Press Monit 2008; 13:65-71. (Pubitemid 351416905)
35. Fagard RH, Stolarz K, Kuznetsova T, Seidlerova J, Tikhonoff V, Grodzicki T, et al. Sympathetic activity, assessed by power spectral analysis of heart rate variability, in white-coat, masked and sustained hypertension versus true normotension. J Hypertens 2007; 25:2280-2285. (Pubitemid 47537922)
36. Neumann SA, Jennings JR, Muldoon MF, Manuck SB. White-coat hypertension and autonomic nervous system dysregulation. Am J Hypertens 2005; 18:584-588. (Pubitemid 40692423)
37. Pierdomenico SD, Bucci A, Costantini F, Lapenna D, Cuccurullo F, Mezzetti A. Twenty-four-hour autonomic nervous function in sustained and 'white coat' hypertension. Am Heart J 2000; 140:672-677.
38. Pannarale G, Isea JE, Coats AJ, Conway J, Sleight P. Cardiac and blood pressure response to mental stress test in reactive hypertensives. Clin Exp Hypertens 1991; A13:1-12.
39. Nakao M, Shimosawa T, Nomura S, Kuboki T, Fujita T, Murata K. Mental arithmetic is a useful diagnostic evaluation in white coat hypertension. Am J Hypertens 1998; 11:41-45. (Pubitemid 28083150)
40. Garcia-Vera MP, Sanz J, F.J. L. Orienting-defense responses and psychophysiological reactivity in isolated clinic versus sustained hypertension. Clin Experiment Hypertens 2007; 29:175-188. (Pubitemid 46744126)
41. Flaa A, Eide IK, Kjeldsen SE, Rostrup M. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study. Hypertension 2008; 52:336-341.
42. Martin C, Cameron J, McGrath B. Mechanical and circulating biomarkers in isolated clinic hypertension. Clin Exp Pharmacol Physiol 2008; 35:402-408. (Pubitemid 351326769)
43. Zhang Y, Thompson AM, Tong W, Xu T, Chen J, Zhao L, et al. Biomarkers of inflammation and endothelial dysfunction and risk of hypertension among inner Mongolians in China. J Hypertens 2010; 28:35-40.
44. Sung KC, Suh JY, Kim BS, Kang JH, Kim H, Lee MH, et al. High sensitivity C-reactive protein as an independent risk factor for essential hypertension. Am J Hypertens 2003; 16:429-433. (Pubitemid 36667795)